

**AMENDMENTS TO THE CLAIMS:**

*Please amend claims as follows:*

**1 – 22. (Cancelled).**

**23. (Withdrawn – Currently amended)** An isolated nucleotide encoding ~~the epitope an antagonist as~~ defined in claim ~~25~~ **1** ~~or an antagonist thereof.~~

**24. (Withdrawn)** The isolated nucleotide of claim 23, having a sequence defined within the sequence of SEQ ID NO: 12.

**25. (New)** An antagonist of a ligand for an epitope or footprint domain for binding integrins, in which said epitope comprises strands A and G of domain 1 of ICAM-4 (SEQ ID NO: 1), wherein said A strand (SEQ ID NO: 2) is defined by amino acid residues 17 to 27 of ICAM-4 and said G strand (SEQ ID NO: 3) is defined by amino acid residues 90 to 100 of ICAM-4, or in which said epitope is modified in that said A strand is replaced by strand F on domain 1 of ICAM-4, wherein said F strand (SEQ ID NO: 4) is defined by amino acid residues 77 to 87 of ICAM-4, or in which said epitope is further defined by amino acid residues W66 on strand E of domain 1 of ICAM-4 and K118 on strand B of domain 2 of ICAM-4, wherein said E strand (SEQ ID NO: 5) is defined by amino acid residues 160 to 170 of ICAM-4 and said B strand (SEQ ID NO: 6) is defined by amino acid residues 116 to 126 of ICAM-4, or an antagonist of a functional homologue of said epitope, and in which said footprint domain comprises a first epitope as defined for said epitope above and a second epitope comprising strand C and strand F of domain 1 of ICAM-4 and a CE loop of domain 2 of ICAM-4, wherein said C strand (SEQ ID NO: 7) is defined by amino acid residues 47 to 54 of ICAM-4, said F strand (SEQ ID NO: 4) is defined by amino acid residues 77 to 87 of ICAM-4 and said CE loop (SEQ ID NO: 8) is defined by amino acid residues 150 to 158 of ICAM-4, or an antagonist of a functional homologue of said footprint domain.

**26. (New)** The antagonist of claim 25, in which said antagonist has or consists essentially of three, four, five, six, seven, eight, nine or more amino acid

residues of said A, C, F or G strands or said CE loop of ICAM-4, or a functional homologue thereof.

**27. (New)** The antagonist of claim 25, in which said antagonist defined by ICAM-4 strand A includes amino acid residues F18, W19 and V20 of ICAM-4.

**28. (New)** The antagonist of claim 27, in which said antagonist or its active site has or consists essentially of an amino acid sequence as defined in SEQ ID NO: 9.

**29. (New)** The antagonist of claim 25, in which said antagonist defined by ICAM-4 strand C includes amino acid residue R52 of ICAM-4.

**30. (New)** The antagonist of claim 25, in which said antagonist defined by ICAM-4 strand F includes amino acid residues T91, W93 and R97 of ICAM-4.

**31. (New)** The antagonist of claim 30, in which said antagonist or its active site has or consists essentially of an amino acid sequence as defined in SEQ ID NO: 11.

**32. (New)** The antagonist of claim 25, in which said antagonist defined by ICAM-4 strand G includes amino acid residues R92, A94, T95, S96 and R97 of ICAM-4.

**33. (New)** The antagonist of claim 32, in which said antagonist or its active site has or consists essentially of an amino acid sequence as defined in SEQ ID NO: 10.

**34. (New)** The antagonist of claim 25, in which said antagonist defined by ICAM-4 CE loop includes amino acid residues E151 and T154 of ICAM-4.